HIV Antibodies
"HIV Antibodies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies reactive with HIV ANTIGENS.
Descriptor ID |
D015483
|
MeSH Number(s) |
D12.776.124.486.485.114.254.150.440 D12.776.124.790.651.114.254.150.440 D12.776.377.715.548.114.254.150.440
|
Concept/Terms |
HIV Antibodies- HIV Antibodies
- Antibodies, HIV
- HIV Associated Antibodies
- Antibodies, HIV Associated
- HIV-Associated Antibodies
- Antibodies, HIV-Associated
- HTLV III Antibodies
- Antibodies, HTLV III
- HTLV III LAV Antibodies
- T-Lymphotropic Virus Type III Antibodies, Human
- HTLV-III-LAV Antibodies
- Antibodies, HTLV-III-LAV
- LAV Antibodies
- Antibodies, LAV
- Lymphadenopathy Associated Antibodies
- Antibodies, Lymphadenopathy Associated
- Lymphadenopathy-Associated Antibodies
- Antibodies, Lymphadenopathy-Associated
- T Lymphotropic Virus Type III Antibodies, Human
- AIDS Antibodies
- Antibodies, AIDS
- HTLV-III Antibodies
- Antibodies, HTLV-III
|
Below are MeSH descriptors whose meaning is more general than "HIV Antibodies".
Below are MeSH descriptors whose meaning is more specific than "HIV Antibodies".
This graph shows the total number of publications written about "HIV Antibodies" by people in this website by year, and whether "HIV Antibodies" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1992 | 1 | 0 | 1 | 1993 | 1 | 0 | 1 | 1994 | 0 | 1 | 1 | 1995 | 0 | 1 | 1 | 1997 | 0 | 1 | 1 | 1999 | 0 | 1 | 1 | 2001 | 1 | 0 | 1 | 2003 | 1 | 0 | 1 | 2005 | 1 | 1 | 2 | 2006 | 0 | 2 | 2 | 2007 | 1 | 1 | 2 | 2008 | 0 | 1 | 1 | 2010 | 0 | 1 | 1 | 2011 | 0 | 1 | 1 | 2012 | 2 | 0 | 2 | 2013 | 2 | 0 | 2 | 2014 | 4 | 2 | 6 | 2015 | 1 | 1 | 2 | 2017 | 2 | 1 | 3 | 2018 | 1 | 2 | 3 | 2019 | 1 | 2 | 3 | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Antibodies" by people in Profiles.
-
Cunningham CK, McFarland EJ, Morrison RL, Capparelli EV, Safrit JT, Mofenson LM, Mathieson B, Valentine ME, Perlowski C, Smith B, Hazra R, Purdue L, Muresan P, Harding PA, Mbengeranwa T, Robinson LG, Wiznia A, Theron G, Lin B, Bailer RT, Mascola JR, Graham BS. Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. J Infect Dis. 2020 07 23; 222(4):628-636.
-
Agazio A, Torres RM. Ushering along B cells to neutralize HIV. Science. 2019 12 06; 366(6470):1197-1198.
-
Hijmans JG, Stockelman KA, Garcia V, Levy MV, Brewster LM, Bammert TD, Greiner JJ, Stauffer BL, Connick E, DeSouza CA. Circulating Microparticles Are Elevated in Treated HIV -1 Infection and Are Deleterious to Endothelial Cell Function. J Am Heart Assoc. 2019 02 19; 8(4):e011134.
-
Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 01 09; 25(1):59-72.e8.
-
Guzzo C, Zhang P, Liu Q, Kwon AL, Uddin F, Wells AI, Schmeisser H, Cimbro R, Huang J, Doria-Rose N, Schmidt SD, Dolan MA, Connors M, Mascola JR, Lusso P. Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation. mBio. 2018 12 11; 9(6).
-
Bricault CA, Kovacs JM, Badamchi-Zadeh A, McKee K, Shields JL, Gunn BM, Neubauer GH, Ghantous F, Jennings J, Gillis L, Perry J, Nkolola JP, Alter G, Chen B, Stephenson KE, Doria-Rose N, Mascola JR, Seaman MS, Barouch DH. Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol. 2018 07 01; 92(13).
-
Zhang P, Gorman J, Geng H, Liu Q, Lin Y, Tsybovsky Y, Go EP, Dey B, Andine T, Kwon A, Patel M, Gururani D, Uddin F, Guzzo C, Cimbro R, Miao H, McKee K, Chuang GY, Martin L, Sironi F, Malnati MS, Desaire H, Berger EA, Mascola JR, Dolan MA, Kwong PD, Lusso P. Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer. Cell Host Microbe. 2018 06 13; 23(6):832-844.e6.
-
McGuire EP, Fong Y, Toote C, Cunningham CK, McFarland EJ, Borkowsky W, Barnett S, Itell HL, Kumar A, Gray G, McElrath MJ, Tomaras GD, Permar SR, Fouda GG. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. J Virol. 2018 01 01; 92(1).
-
Schroeder KM, Agazio A, Torres RM. Immunological tolerance as a barrier to protective HIV humoral immunity. Curr Opin Immunol. 2017 Aug; 47:26-34.
-
Liu Q, Acharya P, Dolan MA, Zhang P, Guzzo C, Lu J, Kwon A, Gururani D, Miao H, Bylund T, Chuang GY, Druz A, Zhou T, Rice WJ, Wigge C, Carragher B, Potter CS, Kwong PD, Lusso P. Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. Nat Struct Mol Biol. 2017 04; 24(4):370-378.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|